Provided by Tiger Trade Technology Pte. Ltd.

JPMORGAN HEALTHCARE LEADERS ETF

59.47
-1.0312-1.70%
Post-market: 60.501.03+1.73%16:10 EDT
Volume:118
Turnover:7K
Market Cap:8.92M
PE:- -
High:59.47
Open:60.50
Low:59.47
Close:60.50
52wk High:64.69
52wk Low:50.40
Shares:150.00K
Float Shares:150.00K
Volume Ratio:1.25
T/O Rate:0.08%
Dividend:0.51
Dividend Rate:0.86%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

LIVE Markets-Big Beauty Faces Growing Threat from AI, Smaller Rivals

Reuters
·
Sep 21

ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO

Dow Jones
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Immunome initiated with a Buy at Alliance Global

TIPRANKS
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Japan Health Ministry Approves Merck’s Keytruda QLEX for Subcutaneous Use Across Keytruda Indications

Reuters
·
Sep 21

Merck’s Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Approved in Japan for Subcutaneous Administration for All Keytruda® (Pembrolizumab) Indications Approved in Japan

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Drug Developer ADARx Seeks $1.74 Billion Valuation in US IPO

Reuters
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 21

Prescient Therapeutics Requests Trading Halt Ahead of Capital Raising Announcement

TIPRANKS
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Lilly, Novo face lawsuits over GLP-1 vision loss risk, WSJ says

TIPRANKS
·
Sep 19

Patients Sue GLP-1 Drugmakers over Risk of Sudden Vision Loss

Dow Jones
·
Sep 19

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Generate Steady Cash

TIPRANKS
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

Eli Lilly reports full FDA approval of Inluriyo combo for certain breast cancers

TIPRANKS
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19